01—Abstract
Summary
Summary of the 8-K filed December 15, 2025. Cited figures are marked; the original filing is the authoritative source.
On December 15, 2025, Cencora, Inc. (NYSE: COR) disclosed a definitive agreement to acquire the majority of the equity interests it does not already own in OneOncology, a physician-led national oncology platform, from TPG and other shareholders.
The transaction values the OneOncology enterprise at $7.4 billiona with an equity value of approximately $6 billion. Cencora will pay about $3.6 billion for the equity and retire $1.3 billion of its existing corporate debt, for total cash consideration of roughly $5.0 billion. OneOncology's affiliated practices and management will retain a minority stake.
The deal was signed December 12, 2025, is expected to close by the end of fiscal Q2 2026, and remains subject to customary conditions, including required regulatory approvals. Cencora plans to fund the deal with new debt, backed by $4.5 billionb in bridge financing commitments. Management stresses that it remains committed to its investment-grade ratings and will prioritize deleveraging afterward.
Cencora expects the acquisition to be roughly EPS-neutral, net of financing costs, to adjusted diluted EPS in the first twelve months after close. Fiscal 2026 guidance of $17.45 to $17.75c adjusted diluted EPS is reiterated but excludes the deal, and the company has paused share repurchases, so results are more likely to land in the lower half of the range. The transaction also lifts long-term guidance.
Adjusted operating income growth is now 7%d to 10%, capital deployment is 3% to 4%, and adjusted diluted EPS growth is 10% to 14%. Management frames the deal as extending its U.S. Healthcare Solutions and management services organization (MSO) footprint in specialty and oncology, building on the recent Retina Consultants of America acquisition. Investors should weigh the strategic upside against leverage, integration, and physician retention risks.
02—Key points
Key Highlights
- Cencora agreed to acquire the majority of the OneOncology equity it does not own from TPG and other shareholders, implying a $7.4 billion enterprise value and roughly $6 billion equity value.
- Total cash consideration is approximately $5.0 billion: about $3.6 billion for equity plus retirement of $1.3 billion of existing corporate debt.
- Funding will come from new debt, supported by $4.5 billion in bridge financing commitments; management reiterated its commitment to investment-grade ratings and prioritized deleveraging.
- Acquisition expected to be approximately EPS-neutral, net of financing costs, to adjusted diluted EPS in the first twelve months after close.
- Fiscal 2026 adjusted diluted EPS guidance of $17.45 to $17.75 was reiterated but excludes the deal; share repurchases are paused and results are more likely in the lower half of the range.
- Long-term guidance raised: adjusted operating income growth of 7% to 10%, capital deployment of 3% to 4%, and adjusted diluted EPS growth of 10% to 14%.
- Closing is targeted by the end of fiscal Q2 2026 and is subject to customary conditions, including required regulatory approvals.
03—Questions
Frequently Asked Questions
How much is Cencora paying for OneOncology, and how is the price structured?
Cencora will pay approximately $3.6 billion for the majority of the equity it does not own and will retire $1.3 billion of its existing corporate debt, for total cash consideration of about $5.0 billion. The OneOncology enterprise is valued at $7.4 billion, with equity value of about $6 billion. OneOncology's affiliated practices and management will keep a minority stake.
How will Cencora finance the transaction, and does it affect the balance sheet?
Cencora plans to fund the deal with new debt and has obtained $4.5 billion in bridge financing commitments. This increases leverage, so the company has committed to maintaining its investment-grade ratings and to prioritizing deleveraging after closing. Investors should watch the size and timing of any permanent debt issuance.
What is the expected impact on earnings per share?
Cencora expects the acquisition to be approximately EPS-neutral, net of financing costs, to adjusted diluted EPS in the first twelve months after close. Fiscal 2026 guidance of $17.45 to $17.75 excludes the deal, and share repurchases are paused, so full-year adjusted EPS is more likely to land in the lower half of that range.
When is the deal expected to close, and what could prevent it?
The transaction is expected to close by the end of Cencora's fiscal 2026 second quarter. Closing is subject to customary conditions, including receipt of required regulatory approvals. The filing's risk factors also flag possible failure to achieve expected synergies, physician and employee retention challenges, and business disruption.
Why is Cencora making this acquisition, and how does it change long-term guidance?
Management positions OneOncology as a way to expand its specialty and management services organization (MSO) capabilities, support oncology practices and pharmaceutical innovators, and build on the recent Retina Consultants of America acquisition. Long-term guidance was raised to adjusted operating income growth of 7% to 10% and adjusted diluted EPS growth of 10% to 14%, reflecting OneOncology's expected long-term contribution.
04—Continue